Added to YB: 2026-10-09
Pitch date: 2026-10-06
EXOZ [bullish]
eXoZymes, Inc.
-27.93%
current return
Author Info
Slack Capital is an investment publication dedicated to sharing only a select few opportunities each year. Through 12 years of investing, I have found that deep research and a focused concentration have consistently outperformed a broad, generalised approach. By making informed, strategic investments, I have been able to generate significant returns while consistently strengthening my confidence in my allocation decisions. At the core of Slack Capital's publication are the offered investment reports, often the result of over 50 hours of research, where all available information on a company is meticulously compiled and filtered into a centralised analysis. Sign up for the newsletter.
Company Info
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing.
Market Cap
$51.2M
Pitch Price
$5.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.72
P/E
-4.59
EV/Sales
N/A
Sector
Biotechnology
Category
growth
eXoZymes’ Path to Computational Biomanufacturing
EXOZ (hold): eXoZymes’ nine-month, $147,000 share of a roughly $747,000 DOE Genesis project is early validation of the proposed work and aims to build AI-powered cell-free digital twins with Berkeley Lab. If accurate and integrated with existing pathway and enzyme-design tools—an investor vision, not guidance—the models could cut experimental cycles and strengthen a flywheel of repeatedly developing, de-risking and retaining high-value molecules before partnering. Accuracy, cross-pathway generalization, integration and commercial-scale performance remain unproven.
Read full article (5 min)